PolyPid Ltd.: PolyPid Announces FDA Acceptance of NDA with Priority Review for D-PLEX100
PolyPid (Nasdaq: PYPD) said the FDA accepted its NDA for D-PLEX100 to prevent surgical site infections in abdominal colorectal surgery and granted Priority Review. The PDUFA target action date is Nov. 28, 2026. FDA found no filing review issues. Acceptance triggers a $15 million milestone from Azurity, completing $30 million in upfront and near-term milestones.
How this was made
The 30-second read
Why it matters
FDA acceptance and Priority Review are concrete regulatory progress markers. The specified PDUFA target date (Nov. 28, 2026) being about a quarter ahead of prior guidance can shift expectations for timing of approval and partner commercialization planning.
Market read
This is a regulatory milestone with a specific FDA action date and a disclosed milestone payment, which can materially change near-term risk and valuation expectations.
What to watch
The article does not disclose any new clinical or CMC fixes; traders should watch for subsequent FDA communications, label scope, and whether the Priority Review translates into a clean approval path.
Background
PolyPid’s D-PLEX100 is a local, controlled-release doxycycline approach for preventing surgical site infections after abdominal colorectal surgery, supported by Phase 3 SHIELD II results.
Ticker impact
PolyPid’s NDA for D-PLEX100 was accepted for filing and granted Priority Review, with a PDUFA target action date of Nov. 28, 2026.
Likely positive near-term bias into the PDUFA window, with volatility around FDA review milestones and any subsequent FDA questions.
The article discloses a primary regulatory event (NDA acceptance plus Priority Review) and a specific action date, which typically matters more than background trial commentary.
Market effects
Supports sentiment for surgical infection prevention and local antibiotic delivery platforms, potentially improving read-through for similar perioperative anti-infective programs.
Primarily US regulatory-driven, with potential knock-on interest from investors tracking FDA timelines for Israeli/US-listed biopharma.
Priority Review can influence global partner expectations and downstream commercialization planning, including non-US markets tied to the same NDA.
Counterpoint
Priority Review shortens the timeline but does not reduce the chance of a complete response or additional data requests; the stock may overreact to the accelerated date.
Key entities
- companyPolyPid Ltd.
Nasdaq-listed biopharmaceutical company whose D-PLEX100 NDA was accepted and granted Priority Review.
- product_candidateD-PLEX100
Lead product candidate for prevention of surgical site infections in abdominal colorectal surgery.
- regulatorFDA
Accepted the NDA for filing and granted Priority Review, setting a Nov. 28, 2026 PDUFA target action date.
- partnerAzurity Pharmaceuticals
Commercialization partner; acceptance triggers a $15 million milestone payment.
